{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:40:29Z","timestamp":1790052029866,"version":"4.0.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s10637-013-9937-8","type":"journal-article","created":{"date-parts":[[2013,2,26]],"date-time":"2013-02-26T09:04:23Z","timestamp":1361869463000},"page":"1217-1227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome"],"prefix":"10.1007","volume":"31","author":[{"given":"Ivana","family":"Gojo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Perl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J.","family":"Norsworthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth S.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tidwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Fleckinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Sausville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,1]]},"reference":[{"key":"9937_CR1","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2741\/1592","volume":"10","author":"D Kim","year":"2005","unstructured":"Kim D, Dan HC, Park S, Yang L, Liu Q, Kaneko S, Ning J, He L, Yang H, Sun M, Nicosia SV, Cheng JQ (2005) AKT\/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci J Virtual Libr 10:975\u2013987","journal-title":"Front Biosci J Virtual Libr"},{"issue":"9","key":"9937_CR2","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1517\/14728220903136775","volume":"18","author":"AM Martelli","year":"2009","unstructured":"Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA (2009) Targeting the PI3K\/AKT\/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 18(9):1333\u20131349. doi:https:\/\/doi.org\/10.1517\/14728220903136775","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"9937_CR3","first-page":"239","volume":"20","author":"AM Martelli","year":"2005","unstructured":"Martelli AM, Tabellini G, Bortul R, Tazzari PL, Cappellini A, Billi AM, Cocco L (2005) Involvement of the phosphoinositide 3-kinase\/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histol Histopathol 20(1):239\u2013252","journal-title":"Histol Histopathol"},{"issue":"21","key":"9937_CR4","doi-asserted-by":"publisher","first-page":"9643","DOI":"10.1158\/0008-5472.CAN-05-0422","volume":"65","author":"CH Brandts","year":"2005","unstructured":"Brandts CH, Sargin B, Rode M, Biermann C, Lindtner B, Schwable J, Buerger H, Muller-Tidow C, Choudhary C, McMahon M, Berdel WE, Serve H (2005) Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 65(21):9643\u20139650. doi:https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0422","journal-title":"Cancer Res"},{"issue":"6","key":"9937_CR5","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/leu.2008.395","volume":"23","author":"N Gallay","year":"2009","unstructured":"Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade C, Attal M, Payrastre B, Demur C, Recher C (2009) The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia 23(6):1029\u20131038. doi:https:\/\/doi.org\/10.1038\/leu.2008.395","journal-title":"Leukemia"},{"issue":"7","key":"9937_CR6","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood-2006-02-003475","volume":"108","author":"SM Kornblau","year":"2006","unstructured":"Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, Estey EH, Andreeff M (2006) Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 108(7):2358\u20132365. doi:https:\/\/doi.org\/10.1182\/blood-2006-02-003475","journal-title":"Blood"},{"issue":"15","key":"9937_CR7","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.1158\/0008-5472.CAN-04-0174","volume":"64","author":"YH Min","year":"2004","unstructured":"Min YH, Cheong JW, Kim JY, Eom JI, Lee ST, Hahn JS, Ko YW, Lee MH (2004) Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res 64(15):5225\u20135231. doi:https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-0174","journal-title":"Cancer Res"},{"issue":"3","key":"9937_CR8","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1182\/blood-2006-12-061283","volume":"110","author":"J Tamburini","year":"2007","unstructured":"Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broet P, Cornillet-Lefebvre P, Lioure B, Ugo V, Blanchet O, Ifrah N, Witz F, Dreyfus F, Mayeux P, Lacombe C, Bouscary D (2007) Constitutive phosphoinositide 3-kinase\/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 110(3):1025\u20131028. doi:https:\/\/doi.org\/10.1182\/blood-2006-12-061283","journal-title":"Blood"},{"issue":"3","key":"9937_CR9","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1182\/blood-2002-11-3429","volume":"102","author":"Q Xu","year":"2003","unstructured":"Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M (2003) Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102(3):972\u2013980. doi:https:\/\/doi.org\/10.1182\/blood-2002-11-3429","journal-title":"Blood"},{"issue":"1","key":"9937_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/leu.2009.209","volume":"24","author":"PY Jotta","year":"2010","unstructured":"Jotta PY, Ganazza MA, Silva A, Viana MB, da Silva MJ, Zambaldi LJ, Barata JT, Brandalise SR, Yunes JA (2010) Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 24(1):239\u2013242. doi:https:\/\/doi.org\/10.1038\/leu.2009.209","journal-title":"Leukemia"},{"issue":"8","key":"9937_CR11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1038\/leu.2009.64","volume":"23","author":"A Larson Gedman","year":"2009","unstructured":"Larson Gedman A, Chen Q, Kugel Desmoulin S, Ge Y, LaFiura K, Haska CL, Cherian C, Devidas M, Linda SB, Taub JW, Matherly LH (2009) The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. Leukemia 23(8):1417\u20131425. doi:https:\/\/doi.org\/10.1038\/leu.2009.64","journal-title":"Leukemia"},{"key":"9937_CR12","doi-asserted-by":"publisher","unstructured":"Morishita N, Tsukahara H, Chayama K, Ishida T, Washio K, Miyamura T, Yamashita N, Oda M, Morishima T (2011) Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia. Pediatr Blood Cancer 59(1):83\u201389. doi:https:\/\/doi.org\/10.1002\/pbc.24034","DOI":"10.1002\/pbc.24034"},{"issue":"41","key":"9937_CR13","doi-asserted-by":"publisher","first-page":"27444","DOI":"10.1074\/jbc.M709703200","volume":"283","author":"J Sun","year":"2008","unstructured":"Sun J, Pedersen M, Ronnstrand L (2008) Gab2 is involved in differential phosphoinositide 3-kinase signaling by two splice forms of c-Kit. J Biol Chem 283(41):27444\u201327451. doi:https:\/\/doi.org\/10.1074\/jbc.M709703200","journal-title":"J Biol Chem"},{"issue":"5","key":"9937_CR14","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3324\/haematol.2009.013797","volume":"95","author":"S Park","year":"2010","unstructured":"Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C, Bouscary D (2010) Role of the PI3K\/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 95(5):819\u2013828. doi:https:\/\/doi.org\/10.3324\/haematol.2009.013797","journal-title":"Haematologica"},{"issue":"3","key":"9937_CR15","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2009-02-206722","volume":"114","author":"A Gutierrez","year":"2009","unstructured":"Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS, Larson R, Zhang J, Protopopov A, Chin L, Pandolfi PP, Silverman LB, Hunger SP, Sallan SE, Look AT (2009) High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114(3):647\u2013650. doi:https:\/\/doi.org\/10.1182\/blood-2009-02-206722","journal-title":"Blood"},{"issue":"5712","key":"9937_CR16","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science 307(5712):1098\u20131101. doi:https:\/\/doi.org\/10.1126\/science.1106148","journal-title":"Science"},{"issue":"7","key":"9937_CR17","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","volume":"129","author":"BD Manning","year":"2007","unstructured":"Manning BD, Cantley LC (2007) AKT\/PKB signaling: navigating downstream. Cell 129(7):1261\u20131274. doi:https:\/\/doi.org\/10.1016\/j.cell.2007.06.009","journal-title":"Cell"},{"issue":"21","key":"9937_CR18","doi-asserted-by":"publisher","first-page":"6732","DOI":"10.1158\/1078-0432.CCR-09-0842","volume":"15","author":"AE Perl","year":"2009","unstructured":"Perl AE, Kasner MT, Tsai DE, Vogl DT, Loren AW, Schuster SJ, Porter DL, Stadtmauer EA, Goldstein SC, Frey NV, Nasta SD, Hexner EO, Dierov JK, Swider CR, Bagg A, Gewirtz AM, Carroll M, Luger SM (2009) A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res 15(21):6732\u20136739. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0842","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9937_CR19","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","volume":"105","author":"C Recher","year":"2005","unstructured":"Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, Benzaquen D, Laurent G, Huguet F, Payrastre B (2005) Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 105(6):2527\u20132534. doi:https:\/\/doi.org\/10.1182\/blood-2004-06-2494","journal-title":"Blood"},{"key":"9937_CR20","doi-asserted-by":"publisher","unstructured":"Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ (2008) A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 14(9):2756\u20132762. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-1372","DOI":"10.1158\/1078-0432.CCR-07-1372"},{"issue":"17","key":"9937_CR21","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1158\/1078-0432.CCR-06-0764","volume":"12","author":"KW Yee","year":"2006","unstructured":"Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, Ferrajoli A, Thomas D, Wierda W, Apostolidou E, Albitar M, O\u2019Brien S, Andreeff M, Giles FJ (2006) Phase I\/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12(17):5165\u20135173. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0764","journal-title":"Clin Cancer Res"},{"issue":"11","key":"9937_CR22","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/sj.onc.1205225","volume":"21","author":"S Sato","year":"2002","unstructured":"Sato S, Fujita N, Tsuruo T (2002) Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21(11):1727\u20131738. doi:https:\/\/doi.org\/10.1038\/sj.onc.1205225","journal-title":"Oncogene"},{"key":"9937_CR23","doi-asserted-by":"publisher","unstructured":"Hahn M, Li W, Yu C, Rahmani M, Dent P, Grant S (2005) Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1\/MEK\/ERK, Akt, and JNK signal transduction pathways. Mol Cancer Ther 4(3):457\u2013470. doi:https:\/\/doi.org\/10.1158\/1535-7163.MCT-04-0137","DOI":"10.1158\/1535-7163.MCT-04-0137"},{"issue":"1","key":"9937_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/sj.leu.2404980","volume":"22","author":"V Papa","year":"2008","unstructured":"Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, McCubrey JA, Martelli AM (2008) Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 22(1):147\u2013160. doi:https:\/\/doi.org\/10.1038\/sj.leu.2404980","journal-title":"Leukemia"},{"issue":"6","key":"9937_CR25","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1158\/0008-5472.CAN-04-2440","volume":"65","author":"M Rahmani","year":"2005","unstructured":"Rahmani M, Reese E, Dai Y, Bauer C, Payne SG, Dent P, Spiegel S, Grant S (2005) Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1\/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 65(6):2422\u20132432. doi:https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-2440","journal-title":"Cancer Res"},{"issue":"22","key":"9937_CR26","doi-asserted-by":"publisher","first-page":"9394","DOI":"10.1158\/0008-5472.CAN-08-2815","volume":"68","author":"PL Tazzari","year":"2008","unstructured":"Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R, Chiarini F, Evangelisti C, Martinelli G, Bontadini A, Cocco L, McCubrey JA, Martelli AM (2008) Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res 68(22):9394\u20139403. doi:https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-2815","journal-title":"Cancer Res"},{"issue":"20","key":"9937_CR27","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.1182\/blood-2008-09-177881","volume":"114","author":"M Rahmani","year":"2009","unstructured":"Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, Harada H, Ferreira-Gonzalez A, Dent P, Grant S (2009) The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K\/Akt and MEK\/ERK1\/2 pathways. Blood 114(20):4507\u20134516. doi:https:\/\/doi.org\/10.1182\/blood-2008-09-177881","journal-title":"Blood"},{"issue":"6","key":"9937_CR28","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1182\/blood-2005-08-3351","volume":"107","author":"D Sampath","year":"2006","unstructured":"Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W (2006) Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood 107(6):2517\u20132524. doi:https:\/\/doi.org\/10.1182\/blood-2005-08-3351","journal-title":"Blood"},{"issue":"4","key":"9937_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.7164\/antibiotics.42.571","volume":"42","author":"I Takahashi","year":"1989","unstructured":"Takahashi I, Saitoh Y, Yoshida M, Sano H, Nakano H, Morimoto M, Tamaoki T (1989) UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. J Antibiot 42(4):571\u2013576","journal-title":"J Antibiot"},{"issue":"7","key":"9937_CR30","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1158\/1078-0432.CCR-06-2793","volume":"13","author":"AN Tse","year":"2007","unstructured":"Tse AN, Carvajal R, Schwartz GK (2007) Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 13(7):1955\u20131960. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2793","journal-title":"Clin Cancer Res"},{"issue":"15","key":"9937_CR31","doi-asserted-by":"publisher","first-page":"5242","DOI":"10.1158\/1078-0432.CCR-03-0534","volume":"10","author":"GP Dasmahapatra","year":"2004","unstructured":"Dasmahapatra GP, Didolkar P, Alley MC, Ghosh S, Sausville EA, Roy KK (2004) In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin Cancer Res 10(15):5242\u20135252. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0534","journal-title":"Clin Cancer Res"},{"issue":"22","key":"9937_CR32","doi-asserted-by":"publisher","first-page":"7450","DOI":"10.1158\/1078-0432.CCR-03-0406","volume":"10","author":"L Ummersen","year":"2004","unstructured":"Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzoomanian R, Alberti D, Wilding G (2004) A phase I trial of perifosine (NSC 639966) on a loading dose\/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10(22):7450\u20137456. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0406","journal-title":"Clin Cancer Res"},{"issue":"9","key":"9937_CR33","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1158\/1078-0432.CCR-06-1832","volume":"13","author":"MJ Edelman","year":"2007","unstructured":"Edelman MJ, Bauer KS Jr, Wu S, Smith R, Bisacia S, Dancey J (2007) Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Clin Cancer Res 13(9):2667\u20132674. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1832","journal-title":"Clin Cancer Res"},{"issue":"12","key":"9937_CR34","first-page":"3671","volume":"96","author":"BD Cheson","year":"2000","unstructured":"Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, L\u00f6wenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL, World Health Organization international working group (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96(12):3671\u20133674","journal-title":"Blood"},{"issue":"24","key":"9937_CR35","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, L\u00f6wenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21(24):4642\u20134649. doi:https:\/\/doi.org\/10.1200\/JCO.2003.04.036","journal-title":"J Clin Oncol"},{"key":"9937_CR36","doi-asserted-by":"publisher","unstructured":"Perl AE, Kasner MT, Shank D, Luger SM, Carroll M (2012) Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res 18(6):1716\u20131725. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2346","DOI":"10.1158\/1078-0432.CCR-11-2346"},{"key":"9937_CR37","doi-asserted-by":"publisher","unstructured":"Bauer KS, Lush RM, Rudek MA, Shih C, Sausville E, Figg WD (2000) A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva. Biomed Chromatogr 14(5):338\u2013343. doi:https:\/\/doi.org\/10.1002\/1099-0801(200008)14:5%3C338::AID-BMC993%3E3.0.CO;2-6","DOI":"10.1002\/1099-0801(200008)14:5%3C338::AID-BMC993%3E3.0.CO;2-6"},{"issue":"2","key":"9937_CR38","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0378-4347(01)00231-6","volume":"759","author":"EW Woo","year":"2001","unstructured":"Woo EW, Messmann R, Sausville EA, Figg WD (2001) Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 759(2):247\u2013257","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"12","key":"9937_CR39","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/S0959-8049(02)00127-2","volume":"38","author":"M Crul","year":"2002","unstructured":"Crul M, Rosing H, de Klerk GJ, Dubbelman R, Traiser M, Reichert S, Knebel NG, Schellens JH, Beijnen JH, ten Bokkel Huinink WW (2002) Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Eur J Cancer 38(12):1615\u20131621","journal-title":"Eur J Cancer"},{"issue":"15","key":"9937_CR40","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1182\/blood-2010-10-316026","volume":"117","author":"J Marvin","year":"2011","unstructured":"Marvin J, Swaminathan S, Kraker G, Chadburn A, Jacobberger J, Goolsby C (2011) Normal bone marrow signal-transduction profiles: a requisite for enhanced detection of signaling dysregulations in AML. Blood 117(15):e120\u2013e130. doi:https:\/\/doi.org\/10.1182\/blood-2010-10-316026","journal-title":"Blood"},{"issue":"3","key":"9937_CR41","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0959-8049(97)89020-X","volume":"33","author":"P Hilgard","year":"1997","unstructured":"Hilgard P, Klenner T, Stekar J, Nossner G, Kutscher B, Engel J (1997) D-21266, a new heterocyclic alkylphospholipid with antitumour activity. Eur J Cancer 33(3):442\u2013446","journal-title":"Eur J Cancer"},{"issue":"12","key":"9937_CR42","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1158\/1078-0432.CCR-04-2346","volume":"11","author":"XY Pei","year":"2005","unstructured":"Pei XY, Dai Y, Rahmani M, Li W, Dent P, Grant S (2005) The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells. Clin Cancer Res 11(12):4589\u20134600. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2346","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9937_CR43","doi-asserted-by":"publisher","first-page":"510","DOI":"10.18632\/oncotarget.290","volume":"2","author":"JK Altman","year":"2011","unstructured":"Altman JK, Sassano A, Platanias LC (2011) Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget 2(6):510\u2013517","journal-title":"Oncotarget"},{"issue":"22","key":"9937_CR44","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1158\/1078-0432.CCR-10-1102","volume":"16","author":"N Chapuis","year":"2010","unstructured":"Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D (2010) Dual inhibition of PI3K and mTORC1\/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 16(22):5424\u20135435. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1102","journal-title":"Clin Cancer Res"},{"issue":"4","key":"9937_CR45","doi-asserted-by":"publisher","first-page":"371","DOI":"10.18632\/oncotarget.477","volume":"3","author":"AM Martelli","year":"2012","unstructured":"Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, Fini M, McCubrey JA (2012) Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget 3(4):371\u2013394","journal-title":"Oncotarget"},{"key":"9937_CR46","doi-asserted-by":"publisher","unstructured":"Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D, Lacombe C, Mayeux P, Bouscary D, Tamburini J (2012) The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia 26(6):1195\u20131202. doi:https:\/\/doi.org\/10.1038\/leu.2011.339","DOI":"10.1038\/leu.2011.339"},{"issue":"1","key":"9937_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ygyno.2012.04.006","volume":"126","author":"S Fu","year":"2012","unstructured":"Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC Jr, Mills GB (2012) Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol 126(1):47\u201353","journal-title":"Gynecol Oncol"},{"issue":"21","key":"9937_CR48","first-page":"3705","volume":"118","author":"A Guidetti","year":"2011","unstructured":"Guidetti A, Locatelli S, Viviani S, Dodero A, Farina L, Russo D, Bulian P, Sorasio R, Nicola MD, Corradini P, Anichini A, Gianni AM, Carlo-Stella C (2011) Phosphorylation levels of extracellular-signal regulated kinase (ERK) and AKT in circulating lymphocytes predict response to targeted therapy with kinase inhibitors in refractory\/relapsed Hodgkin lymphoma patients. ASH Annual Meeting Abstracts 118(21):3705","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"4","key":"9937_CR49","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1365-2141.2012.09173.x","volume":"158","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ, Richardson PG, Zimmerman T, Alsina M, Kaufman JL, Kandarpa M, Kraftson S, Ross CW, Harvey C, Hideshima T, Sportelli P, Poradosu E, Gardner L, Giusti K, Anderson KC (2012) Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed\/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol 158(4):472\u2013480","journal-title":"Br J Haematol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9937-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-013-9937-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9937-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-9937-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:38:30Z","timestamp":1678509510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-013-9937-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["9937"],"URL":"https:\/\/doi.org\/10.1007\/s10637-013-9937-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"5 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}